Get started
Work

643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors

Year: 2021
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2021.08.1156
Authors: H-T. Arkenau, T. Guthrie, T. Mekhail, D. Cortinovis, L. Antonuzzo, J.Y. Bruce, N. Gabrail, I. Anderson, S.C. Oh, S.Y. Oh, L. Nott, M.A. Shah, R.E. Sanborn, D-Y. Oh, J.Y. Cho, C-C. Lin, A. Lee, Y. Wang, Z. Wang, A. Sher
Institutions: Sarah Cannon Research Institute, 21st Century Oncology (United States), AdventHealth Orlando, AdventHealth, Azienda Ospedaliera San Gerardo, Azienda Ospedaliero-Universitaria Careggi, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Gabrail Cancer Center, Dong-A University Hospital, Korea University Guro Hospital, Royal Hobart Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, Providence Portland Medical Center, Seoul National University Hospital, Yonsei University, Gangnam Severance Hospital, National Taiwan University Hospital, The University of Texas at Tyler, Seagen (United States), Stony Brook University Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3204650873
FWCI: 0.121
Cites:
Cited by: 2
Related to: 10